News & Events

Learn more about ReForm Biologics and our commitment to innovation in biotherapeutics.

ReForm Biologics Announces the Issuance of Chinese Patent for Therapeutic Protein Formulations

ReForm Biologics Expands Its Intellectual Property Estate to Improve Patient Care. Announced the expansion of its patent portfolio with issuance of its first patent in China, Patent No. CN ZL20158003.

James Sherblom Appointed Board Chairman to Lead ReForm Biologics’ New Business Strategy

ReForm Biologics today announced it will expand its focus to develop a new generation of bio-innovative biologic medicines in-house to improve patient access, safety and convenience. As well, James (Jim) Sherblom has joined the board of directors of ReForm as chairman to lead the shift in strategy.

ReForm Biologics Announces the Issuance of U.S. and Japanese Patents for Therapeutic Protein Formulations

The U.S. patent, entitled “Stabilizing Excipients for Therapeutic Protein Formulations,” provides ReForm exclusive rights to therapeutic protein formulations that include a new class of stabilizers that significantly reduce protein aggregation and stabilize proteins during storage. These stabilizers offer a promising alternative to conventional surfactants. With ReForm’s stable surfactant replacements for polysorbates in biologic formulations, biopharmaceutical companies may reduce protein aggregation and ultimately improve patient care.

ReForm Biologics and MilliporeSigma Announce a Licensing Agreement for Excipient Development and Commercialization

ReForm Biologics LLC, a pharmaceutical technology company developing innovative platforms to improve biologic formulations and MilliporeSigma today announced a global license agreement and collaboration to commercialize proprietary ReForm excipients used in biotherapeutic formulations. The Life Science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

ReForm Biologics Announces Issuance of U.S. Patent on Additional Excipients for Therapeutic Protein Formulations

ReForm Biologics, a pharmaceutical technology company developing innovative platforms to improve biologic formulations, expanded its patent portfolio with the issuance of U.S. Patent No. 10,478,498 (the ‘498 patent).

ReForm Biologics Announces Two New Technology Presentations at Bioprocessing Summit 2019

Presentations on bio-layer interferometry for improved formulation screening and use of new excipients to prevent particle formation.

ReForm Biologics Announces the Appointment of Alan Herman, Ph.D. and Fred Larimore, Ph.D. to Scientific Advisory Board

ReForm Biologics, a pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, today announced the appointment of Alan Herman, Ph.D. and Fred Larimore, Ph.D. to the company’s Scientific Advisory Board (SAB).

ReForm Biologics Announces An Evaluation Agreement for Enhancing Formulation of Two Clinical-stage Pipeline Programs

ReForm Biologics, a pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, today announced a new customer. ReForm will perform feasibility studies for Bayer AG utilizing its innovative biotherapeutic technologies.

ReForm Biologics Announces Issuance of U.S. Patent on Stabilizing Excipients for Therapeutic Protein Formulations

ReForm Biologics, a pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, expanded its patent portfolio with the issuance of U.S. Patent No. 10,279,048 (the ‘048 patent). The patent, entitled “Stabilizing Excipients for Therapeutic Protein Formulations,” provides ReForm exclusive rights to certain formulations and methods comprising an innovative new class of stabilizers that can significantly reduce protein aggregation and stabilize proteins during storage. These stabilizers offer a promising alternative to conventional polysorbate surfactants.

ReForm Biologics Announces Collaboration Agreement with Astellas Pharma Inc.

ReForm Biologics, a privately-held pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, today announced a collaboration with Astellas Pharma Inc. to reduce the viscosity of an Astellas clinical-stage biological pipeline program. Reform’s technology platform transforms the formulation of biotherapeutics in order to enable alternative dosing, improve manufacturing efficiency and extend product life-cycles.

ReForm Biologics Announces New Patent on Surfactant Replacement Excipients to Stabilize Antibody-Based Therapeutics

New surfactant replacement offers a promising alternative to polysorbates for stabilizing proteins

ReForm Biologics and KBI Biopharma Announce Strategic Partnership to Improve Biopharmaceutical Formulations and Development

Collaboration will provide clients competitive advantages, improve speed to market

KBI makes equity investment in ReForm Biologics along with existing investors

ReForm Biologics and KBI Biopharma, Inc., (KBI) today announced a strategic partnership to make improved biopharmaceutical formulations.

ReForm Biologics Secures New Patent Expanding Coverage of Key Excipient Formulation for Antibody-Based Therapeutics

ReForm Biologics Announces Issuance of U.S. Patent for New Excipient to Improve Antibody-Based Therapeutics

ReForm Biologics to present at the 13th annual PEGS Summit

ReForm Biologics, a pharmaceutical technology company developing an innovative platform to improve biologic formulations, announced today the issuance of U.S. patent 9,605,051 (the ‘051 patent) for one of its new excipient formulations.

ReForm Biologics Appoints John M. Sorvillo, Ph.D., as Chief Executive Officer

Dr. Sorvillo brings over 25 years of experience leading the development and licensing of technologies, from discovery platforms and research programs to pre-clinical and clinical products, across a range of therapeutic areas.